Actively Recruiting
Evaluating Oral Paclitaxel Solution Plus Fruquintinib Versus Investigators Chemotherapy Choice as Second-Line Treatment for Advanced Gastric and Gastroesophageal Cancer
Led by Harbin Medical University · Updated on 2026-10-28
150
Participants Needed
15
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of oral paclitaxel solution combined with fruquintinib as a second-line treatment for adults with advanced or metastatic gastric or gastroesophageal junction cancer. This open-label, randomized trial compares this combination to chemotherapy selected by the investigator. The study aims to provide new options for patients whose cancer has progressed after first-line therapy. Participants receive either oral paclitaxel solution plus fruquintinib or investigator-chosen chemotherapy. The oral paclitaxel is given in 28-day cycles on days 1, 8, and 15, while fruquintinib is taken daily for 3 weeks followed by a week off. The comparator group receives injectable chemotherapy agents per clinical guidelines. Treatment continues until disease progression, unacceptable side effects, withdrawal, or study completion. During the study, participants undergo regular assessments including tumor measurements, survival status, and quality of life questionnaires. Safety is monitored from the first dose through 30 days after the last dose. Researchers measure progression-free survival as the primary outcome within 1 year and track overall survival up to 3 years. The total participation duration depends on treatment response and study timelines.
CONDITIONS
Brief Title
Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
Research Team
Y
Yanqiao Zhang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here